OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Sunday morning. The firm issued a sell rating on the stock.

Other research analysts have also issued reports about the stock. Benchmark reissued a speculative buy rating and issued a $5.00 target price on shares of OncoCyte in a report on Monday, April 15th. Needham & Company LLC reaffirmed a buy rating and set a $4.25 price objective on shares of OncoCyte in a research note on Thursday, May 16th. Finally, Stephens reaffirmed an equal weight rating and set a $4.00 price objective on shares of OncoCyte in a research note on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus target price of $4.06.

OncoCyte Trading Down 2.7 %

NASDAQ:OCX traded down $0.08 during midday trading on Friday, reaching $2.87. 11,869 shares of the stock traded hands, compared to its average volume of 43,051. The company has a fifty day moving average of $2.94 and a 200 day moving average of $2.92. OncoCyte has a 12 month low of $2.08 and a 12 month high of $4.34.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) EPS for the quarter. The firm had revenue of $0.18 million for the quarter. OncoCyte had a negative net margin of 2,905.14% and a negative return on equity of 135.45%. On average, research analysts predict that OncoCyte will post -2.58 earnings per share for the current year.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.